Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | FOS | P01100 | 1/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115230 | 1.00 | KMT2A (0.64) | KMT2AKDM4EALDH1A1TRPV1ACHE | |
| SCHEMBL11467113 | 0.88 | ACHE (0.57) | KMT2AKDM4EALDH1A1ACHEHPGD | |
| SCHEMBL11467112 | 0.88 | ACHE (0.57) | KMT2AKDM4EALDH1A1ACHEHPGD | |
| SCHEMBL6787525 | 0.86 | ALOX5 (0.53) | KMT2AKDM4EALDH1A1TRPV1ACHE | |
| SCHEMBL6786109 | 0.84 | ACHE (0.56) | KMT2AALDH1A1ACHEMEN1NPC1 | |
| SCHEMBL3123638 | 0.83 | GPR183 (0.72) | KMT2AKDM4EALDH1A1TRPV1HPGD | |
| SCHEMBL30887536 | 0.83 | PELI1 (0.62) | KMT2AKDM4EALDH1A1TRPV1HPGD | |
| SCHEMBL3123635 | 0.83 | GPR183 (0.72) | KMT2AKDM4EALDH1A1TRPV1HPGD | |
| SCHEMBL30738392 | 0.82 | RAB9A (0.65) | KMT2AKDM4EALDH1A1TRPV1ACHE | |
| SCHEMBL28339476 | 0.82 | RAB9A (0.65) | KMT2AKDM4EALDH1A1TRPV1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | disclosed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-7122561-B2 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20040061142-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2004-04-01 | — | — | US | disclosed |
| US-6680391-B2 | PIPERINE AND ANALOGUES OR DERIVATIVES FOR THE TREATMENT OF SKIN CONDITIONS TREATABLE BY STIMULATING MALENOCYTE PROLIFERATION, SUCH AS VITILGO, AND ALSO FOR SKIN CANCER | BTG INTERNATIONAL LIMITED (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20020168369-A1 | Treatment of skin conditions | BTG INTERNATIONAL LIMITED | 2002-11-14 | — | — | US | disclosed |
| US-6346539-B1 | ADMINISTERING PIPERINE DERIVATIVE TO TREAT VITILIGO AND MELANOMA; STIMULATING MELANOCYTE PROLIFERATION; ANTICARCINOGENIC AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | KMT2A 1722/4885KDM4E 2120/4885ALDH1A1 36/4885 |
| US-20020168369-A1 | Treatment of skin conditions | TYR, MC1R, MITF | KMT2A 620/4885KDM4E 643/4885ALDH1A1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.